C643 Cells
| Unit |
3 x 10^6 cells/ml |
|---|---|
| Cell Type |
Tumor Cells |
| Tissue Type |
Head-Neck cancer cell lines |
| Organism |
Human |
| Donor History |
Anaplastic thyroid carcinoma |
| Growth Properties |
Monolayer ,adherent |
| Growth Conditions |
Culture medium: RPMI 1640 ,w: 2.0 mM stable Glutamine ,w: 2.0 g/L NaHCO3 (Cytion article number 820700a). Supplements: Supplement the medium with 10% FBS. Dissociation reagent: Accutase. Seeding density: 1 x 10⁴ cells/cm² will yield in a confluent layer in about 3 days. Freeze medium: As a cryopreservation medium ,we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability ,or CM-1 (Cytion catalog number 800100) ,which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. Incubation atmosphere: 37°C ,5% CO2 ,humidified atmosphere. |
| Immortalization Method | |
| Full Information |
The cell line C643 was established from a fine-needle biopsy of an anaplastic thyroid carcinoma of a 76-year-old man by Mark et al. in 1987. The patient died within 5 months after diagnosis. Demonstration of thyroglobulin mRNA ascertained a thyroid epithelial origin of the cell line. C643 cells emerge as a valuable tool for thyroid cancer research.
These cells originated from human thyroid cancer tissue and represented metastatic PTC, FTC, and ATC. Their genetic makeup reflects the common mutations observed in thyroid cancer, such as alterations in BRAF, RAS, and PI3K genes, which activate critical signalling pathways.
This makes C643 cells an ideal model for investigating the mechanisms involved in thyroid cancer development and progression. Furthermore, C643 cells are a crucial resource for testing potential targeted therapies.
Their inclusion in preclinical studies can aid in identifying and evaluating novel compounds that specifically target the altered signalling pathways implicated in thyroid cancer. By accurately representing human thyroid cancer, C643 cells contribute to developing more effective treatments for patients with advanced thyroid cancer.
Společnost Cytion vznikla v roce 2004 v německém Heidelbergu s jasným vědeckým posláním: dodávat ověřené lidské a zvířecí buněčné linie bez kontaminace, připravené za přísně kontrolovaných laboratorních podmínek.
Postupně se vypracovala ve spolehlivou buněčnou banku, která slouží akademickým laboratořím, biotechnologickým firmám i farmaceutickým výzkumným týmům po celém světě. Klade přitom důraz na reprodukovatelnost výsledků, přísnou kontrolu kvality a dlouhodobá partnerství.
Mikrobiologické aplikace
NGS
Rapid testy
PCR plasty
Třepačky
Suché lázně
Fluorometry
Buněčné kultury
PCR, qPCR, RT
Detekce Mycoplasmat
Reverzní transkripce
Alergie
Intolerance
Elisa
Imunologické analyzátory
Veterinární imunologie
Alergie u zvířat
Intolerance u zvířat
Čtečky identifikačních čipů
Termočipy
Biochemie
Imunoanalýza

